Eva Edwards
Family · Manchester, KYNPI 1396964102
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 60.9% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $5,664 and has fallen 75.3% since, to $1,399 in 2025. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 495 payments — averaging $28.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$636
- Indivior Inc.$394
- Otsuka America Pharmaceutical, Inc.$384
- Braeburn Inc.$352
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$6,87549%
- Travel & lodging$3162%
- Food & beverage$6,83249%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $8,535 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 157 | $1,490 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $636 |
| Indivior Inc. | 17 | $394 |
| Otsuka America Pharmaceutical, Inc. | 20 | $384 |
| Braeburn Inc. | 17 | $352 |
| Biodelivery Sciences International, Inc. | 30 | $279 |
| Amgen | 14 | $266 |
| Alkermes, Inc. | 12 | $252 |
| AstraZeneca | 9 | $181 |
| Lilly USA, LLC | 11 | $166 |
| Axsome Therapeutics, Inc. | 7 | $163 |
| Ardelyx, Inc. | 6 | $127 |
| Novo Nordisk | 8 | $121 |
| Vanda Pharmaceuticals Inc. | 6 | $120 |
| Redhill Biopharma Inc. | 6 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Pfizer | 4 | $69 |
| Dexcom, Inc. | 3 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Nestle Healthcare Nutrition Inc. | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Boston Scientific | 1 | $27 |
| Gilead | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| GSK | 1 | $17 |
| Smith+Nephew | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Novartis | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$6,875
How this compares
$14,023 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 11 | $25,901 |
| MounjaroTirzepatide | 14 | $14,549 |
| LinzessLinaclotide | 25 | $13,045 |
| UbrelvyUbrogepant | 12 | $11,620 |
| FarxigaDapagliflozin Propanediol | 13 | $8,508 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 72 | $7,666 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $7,096 |
| Vilazodone Hcl | 18 | $1,569 |
| Megestrol Acetate | 15 | $966 |
| Omega-3 Acid Ethyl Esters | 24 | $631 |
| Ibuprofen | 31 | $512 |
| Ondansetron OdtOndansetron | 11 | $328 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $311 |
| Omeprazole | 38 | $274 |
| Testosterone Cypionate | 17 | $264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,490 | $25,90111 claims |
| AbbVieLinzess, Ubrelvy | $8,535 | $24,66537 claims |
| Lilly USA, LLCMounjaro | $166 | $14,54914 claims |
| AstraZenecaFarxiga | $181 | $8,50813 claims |
| Indivior Inc.Suboxone | $394 | $7,09616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Manchester
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
- Carrie Parrish NyekanBowling Green$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.